VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,000 | +100.0% | 70 | 0.0% | 0.00% | – |
| Q1 2018 | $1,000 | 0.0% | 70 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | -75.0% | 70 | -74.1% | 0.00% | -100.0% |
| Q3 2017 | $4,000 | -20.0% | 270 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $5,000 | -37.5% | 270 | -62.8% | 0.00% | -33.3% |
| Q1 2017 | $8,000 | -27.3% | 725 | 0.0% | 0.00% | -25.0% |
| Q4 2016 | $11,000 | -15.4% | 725 | +38.1% | 0.00% | -33.3% |
| Q3 2016 | $13,000 | +18.2% | 525 | 0.0% | 0.01% | +20.0% |
| Q2 2016 | $11,000 | -21.4% | 525 | 0.0% | 0.01% | -28.6% |
| Q1 2016 | $14,000 | -73.6% | 525 | 0.0% | 0.01% | -74.1% |
| Q4 2015 | $53,000 | -43.6% | 525 | 0.0% | 0.03% | -47.1% |
| Q3 2015 | $94,000 | -19.7% | 525 | 0.0% | 0.05% | -15.0% |
| Q2 2015 | $117,000 | +12.5% | 525 | 0.0% | 0.06% | +13.2% |
| Q1 2015 | $104,000 | +38.7% | 525 | 0.0% | 0.05% | +35.9% |
| Q4 2014 | $75,000 | – | 525 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |